腹部超声在肝细胞癌监测中的未来角色
腹部超声是目前在高危患者中验证最充分的肝细胞癌监测策略,是唯一完成全部五个验证阶段的模态,由高年资超声医师在大容量中心操作时可实现高敏感度和特异度。但超声存在操作者依赖性和临床实践中敏感度不一等局限,且对肥胖或非病毒性肝病患者早期肝细胞癌检测敏感度较低。基于影像和血液的监测策略(如简化MRI和生物标志物组合)可能克服部分局限,未来可能从一刀切转向基于个体特征的精准筛查,超声仍可能继续发挥重要但有所减弱的监测作用。
要点
- 腹部超声是唯一完成全部五个验证阶段的肝细胞癌监测策略,由专家在高容量中心操作时敏感度和特异度高。
- 超声监测存在操作者依赖性和临床实践中敏感度不一,肥胖或非病毒性肝病患者早期肝细胞癌检测敏感度较低。
- 简化MRI和生物标志物组合等策略在II期和III期生物标志物研究中表现良好,正在进行前瞻性验证。
核心结论
- 腹部超声目前是验证最充分的肝细胞癌监测策略,但存在操作者依赖和特定人群敏感度较低等局限;未来可能转向基于个体特征的精准筛查,超声仍可能继续发挥重要但有所减弱的监测作用。
研究设计与样本
- 原文为综述,未报告系统检索范围与纳入文献数量,讨论腹部超声作为肝细胞癌监测策略的验证阶段、局限及新兴替代策略。
诊断标准与关键数值
- 腹部超声是唯一被显示已完成全部五个验证阶段的肝细胞癌监测模态,由高容量中心的专家超声医师操作时可达到高敏感度和特异度。
- 超声对早期肝细胞癌的检测敏感度在肥胖或非病毒性肝病患者中较低,这些人群在监测人群中日益常见。
- 简化MRI和生物标志物组合等基于影像和血液的监测策略在II期和III期生物标志物研究中显示有前景的检测性能,正在进行前瞻性验证。
临床应用与阅片要点
- 原文指出未来可能从一刀切方法转向精准筛查,即根据个体患者特征选择「最佳」检测,超声可能继续发挥重要但有所减弱的监测作用。
局限性
- 超声存在操作者依赖性,临床实践中敏感度不一。
- 超声对早期肝细胞癌的检测敏感度在肥胖或非病毒性肝病患者中较低,而这些人群在监测人群中日益常见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Abdominal US is currently the best-validated surveillance strategy for hepatocellular carcinoma (HCC) in at-risk patients. It is the only modality shown to have completed all five phases of validation and can achieve high sensitivity and specificity for HCC detection, especially when conducted by expert sonographers in high-volume centers. However, US also has limitations, including operator dependency and varying sensitivity in clinical practice. Further, the sensitivity of US for early-stage HCC detection is lower in patients with obesity or nonviral liver disease, increasingly common populations undergoing surveillance. Imaging-based and blood-based surveillance strategies, including abbreviated MRI and biomarker panels, may overcome some limitations of US-based surveillance. Both strategies have promising test performance in phase II and phase III biomarker studies and are undergoing prospective validation. Considering the variation in HCC risk and test performance between patients, there will likely be a shift away from a one-size-fits-all approach and toward precision screening, in which the "best" test is selected based on individual patient characteristics. In this upcoming era of precision HCC screening among patients with cirrhosis, US will likely continue to have an important, albeit reduced, surveillance role.
引用
- Mendiratta-Lala M, Fetzer D, Kamaya A, et al. The Future Role of Abdominal US in Hepatocellular Carcinoma Surveillance. Radiology. 2024. PMID: 38742973. doi:10.1148/radiol.232624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。